EUROPEAN PSYCHEDELIC INDUSTRY SURVEY 2026-2027EUROPEAN PSYCHEDELIC INDUSTRY SURVEY 2026-20271. What is your organization’s primary activity? Psychedelic drug development Clinical research Contract research organization (CRO) Active Pharmaceutical Ingredient (API) manufacturing Finished product manufacturing Compounding / pharmacy Mental health clinic Biotechnology / synthetic development Consulting / regulatory services Academic research Other2. In which country does your organization primarily operate? Portugal Spain Germany Netherlands Switzerland United Kingdom Denmark Czech Republic Other European country Outside Europe3. What stage best describes your organization? Early research stage Pre-clinical development Clinical trials Preparing for commercialization Commercial operations4. What is your organization’s current GMP (Good Manufacturing Practice) readiness level? No GMP activities initiated Early GMP planning Partial GMP implementation Advanced GMP implementation GMP certified operation5. Which areas represent your biggest current challenges? (Select up to 3) Regulatory uncertainty GMP compliance Clinical scalability Funding / investment Manufacturing capability Quality systems Access to qualified personnel Supply chain / sourcing Validation & qualification Market uncertainty6. Which quality and compliance systems are currently implemented? (Multiple answers allowed) Standard Operating Procedures (SOPs) Quality Management System (QMS) Corrective and Preventive Actions (CAPA) Risk Management Change Control Good Documentation Practices (GDP) Internal audits None of the above7. How would you rate your organization’s operational and technical maturity? Very low Low Moderate High Very high8. Which statement best describes your manufacturing or research environment? Basic laboratory environment Research-grade controlled environment Pilot-scale operation GMP-compliant cleanroom facility Advanced pharmaceutical-grade operation9. What is the greatest operational or regulatory risk currently affecting your organization? Regulatory delays Clinical trial uncertainty GMP non-compliance Funding limitations Manufacturing limitations Talent shortage Supply chain instabilit10. How frequently does your organization provide GMP or compliancerelated training? Monthly Quarterly Annually Occasionally No formal training11. What level of investment is currently being made in quality, compliance and operational infrastructure? Very low Low Moderate High Very high12. What do you believe is the biggest barrier to psychedelic industry growth in Europe? Regulation Limited clinical evidence Public perception Investment limitations Manufacturing capacity Lack of qualified professionals Reimbursement / healthcare adoption13. Which area requires the greatest external support? (Select up to 2) GMP implementation Regulatory Affairs Validation & Qualification Clinical operations Quality Assurance Facility design Training Manufacturing14. How do you expect the European psychedelic industry to evolve over the next 5 years? Rapid growth Moderate growth Stable market Slow growth Uncertain15. Would you like to receive the final industry benchmark report? Yes NoSubmit Form
